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OPEN
ORIGINAL ARTICLE
Decreased NOX2 expression in the brain of patients with
bipolar disorder: association with valproic acid prescription
and substance abuse
T Seredenina1,5, S Sorce2,5, FR Herrmann3, X-J Ma Mulone1, O Plastre1, A Aguzzi2, V Jaquet1,5 and K-H Krause1,4,5
Neuroinﬂammation and increased oxidative stress are believed to contribute to the development of psychiatric diseases. Animal
studies have implicated NADPH oxidases (NOX) as relevant sources of reactive oxygen species in the brain. We have analyzed the
expression of NOX isoforms in post-mortem brain samples from patients with psychiatric disorders (schizophrenia, bipolar disorder)
and non-psychiatric subjects. Two collections from the Stanley Medical Research Institute were studied: the Array Collection (RNA,
35 individuals per group), and a neuropathology consortium collection (parafﬁn-embedded sections, 15 individuals per group).
Quantitative PCR analysis revealed expression of NOX2 and NOX4 in prefrontal cortex. No impact of psychiatric disease on NOX4
levels was detected. Remarkably, the expression of NOX2 was speciﬁcally decreased in prefrontal and cingulate cortices of bipolar
patients, as compared with controls and schizophrenic patients. NOX2 expression was not statistically associated with demographic
parameters and post-mortem interval, but correlated with brain pH. Immunostaining demonstrated that NOX2 was predominantly
expressed in microglia, which was corroborated by a decrease in the microglial markers CD68 and CD11b in the cingulate cortex of
bipolar disorder patients. The analysis of potentially confounding parameters showed association of valproic acid prescription and
heavy substance abuse with lower levels of NOX2. Taken together, we did not observe changes of NOX2 in schizophrenic patients,
but a marked decrease of microglial markers and NOX2 in the brain of bipolar patients. This might be an underlying feature of
bipolar disorder and/or a consequence of valproic acid treatment and substance abuse.
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INTRODUCTION
Psychiatric diseases, including depression, bipolar disorder (BD)
and schizophrenia (SZ), are a major challenge to public health.
Mechanisms underlying their pathogenesis are still poorly under-
stood, but evidence points toward a combination of genetic and
environmental factors. Patients with mental disorders are given
symptomatic treatments, such as antipsychotics (for example,
clozapine) for schizophrenics, mood stabilizers (lithium, valproic
acid (VPA)) for bipolar patients. Many of these drugs have multiple
modes of action, including anti-oxidative1 and anti-inﬂammatory
activities.2
Although BD and SZ are distinct diagnoses, neuropathological
differences and biochemical quantitative biomarkers distinguish-
ing the two disorders are virtually non-existing. SZ and BD
symptoms are overlapping and patients are often given similar
treatments. At the neuropathological level, most evidence argues
for a contribution of neuroinﬂammation, dysfunction in glutamate
neurotransmission, altered microglial function and oxidative
stress. Changes in reactive oxygen species (ROS) generation are
commonly observed in neuronal disorders and psychiatric
diseases make no exception. Oxidative modiﬁcations are docu-
mented in SZ or BD patients. This includes higher levels of 4-
hydroxynonenal (peroxidized lipids),3 oxidized guanine in post-
mortem brain samples4,5 as well as increased thiobarbituric acid
reactive substances (byproducts of lipid peroxidation)6 and
decreased levels of intracellular antioxidants in the blood.7 Also,
plasma levels of the oxidized form of cysteine were found to be
elevated in schizophrenic8,9 and bipolar patients. Similarly, several
animal models of psychosis recapitulate observations made in
humans and present increased oxidation in both central nervous
system (CNS) parenchyma and the blood (reviewed in ref. 10). It
therefore has been speculated, that the increased oxidative stress
in the CNS is due to an increased ROS generation (see below) and/
or to a decrease in antioxidant capacity and in enzymes mediating
ROS degradation. For example, genetic associations between
polymorphisms in enzymes involved in the glutathione synthesis
and SZ have been described,11,12 which might account for low
glutathione levels found in SZ.13 Sources of ROS in the CNS are
multiple, and their relative contribution to oxidative stress is a
subject of intense investigations. NADPH oxidases (NOX), in
particular, the phagocyte NADPH oxidase NOX2 might be
important.14 A role for NOX2 in psychiatric disorders was ﬁrst
proposed in a study from Behrens and collaborators, which use a
drug-induced model of psychosis (administration of the NMDA
antagonist ketamine to mice). The authors proposed that
increased ROS generation by neuronal NOX2 is causative in
psychogenesis and induced the loss of parvalbumin-positive
neurons, a key pathological hallmark of the schizophrenic brain.
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Interestingly, ketamine, has received much attention as a
promising drug for the treatment of major depression,15 raising
the possibility that some fundamental differences in redox
systems regulate SZ and depressive psychiatric disorders.
Although animal models of psychosis may shed light on several
redox-dependent processes, translation of these ﬁndings to
human is required. Clinical trials using the reducing agent N-
acetylcysteine have shown encouraging results on some speciﬁc
symptoms of SZ and BD (reviewed in ref. 16). However, redox
mechanisms in the human brain and their relationship to
psychiatric diseases remain insufﬁciently understood. Clinical
studies using material collected from psychiatric patients should
help ﬁlling the gap between human and mouse studies, and
address the role of NOX in psychiatric diseases. In this study, we
investigated the expression of NOX in the brain of patients
diagnosed with BD or SZ.
MATERIALS AND METHODS
Post-mortem brain samples
For the studies of gene expression, we used mRNA from cingulate cortex
and prefrontal cortex (PFC) from the Array Collection provided by Stanley
Medical Research Institute. Selection of samples, informed consent and
criteria of exclusion are documented in http://www.stanleyresearch.org/
brain-research. The collection consists of 105 brains from patients
diagnosed with SZ, BD and unaffected controls (35 cases in each group).
Demographic information is provided in Supplementary Table S1.
For immunostaining, we used ﬁxed parafﬁn 10 μm thick sections from
anterior cingulate cortex from the Neuropathology Consortium collection
provided by Stanley Medical Research Institute. This collection consists of
60 brains from patients diagnosed with SZ, BD, depression and unaffected
controls (15 each). In this study, we focused on three groups (SZ, bipolar
and controls) matched by age, sex, race, post-mortem interval, pH and side
of brain. Diagnosis and socio-demographic distribution of patients
considered in this study are shown in Supplementary Table S2. The study
was approved by the Stanley Medical Research Institute.
Real-time quantitative polymerase chain reaction
Total RNA (500 ng) was used for cDNA synthesis using the superscript II kit
according to the manufacturer’s instructions (Invitrogen, Basel, Switzer-
land). Real-time PCR was performed using SYBR green assay on a 7900HT
SDS systems from ABI at the Genomics Platform, National Center of
Competence in Research Frontiers in Genetics, Geneva. The efﬁciency of
each primer was veriﬁed with serial dilutions of cDNA. Relative expression
levels were calculated by normalization to geometric mean of the three
house-keeping genes (GAPDH, β-2-microglobulin and EEF1A1) as
described previously.17 The highest normalized relative quantity was
arbitrarily designated as a value of 1. Fold-changes were calculated from
the quotient of means of these normalized quantities and reported as ± s.e.
m. Sequences of all primers used in this study are provided in
Supplementary Table S3. Threshold cycle (Ct) values for NOX isoforms
corresponding to the intersection between an ampliﬁcation curve and
a threshold line set at 0.20 by the software are provided in Figure 1a.
Speciﬁcity of NOX2 and NOX4 primers was veriﬁed by subcloning the
generated amplicons using the TOPO TA Cloning Kit (Thermo Fischer
Scientiﬁc, Reinach, Switzerland) followed by sequencing at Microsynth
(Balgach, Switzerland).
Immunohistochemistry and imaging
Brain sections were deparafﬁnized through graded alcohols, subjected
to heat-induced epitope retrieval for 15 min in 0.01 mol l− 1 citrate buffer
(pH 6), and incubated overnight at 4 °C in PBS-0.3% Triton-X100 with the
monoclonal anti-human NOX2 antibody Mo4818 (1:250 LSBio LS-C85347,
Seattle, WA, USA). Sections were then incubated for 1 h at room tempera-
ture with speciﬁc biotinylated secondary antibody (1:100, Vector Labora-
tories, Peterborough, UK) and, after several washes in PBS, for 1 h in
horseradish peroxidase-avidin/biotin complex solution (1:100, Vector
Figure 1. Expression of NADPH oxidases (NOX) mRNA in prefrontal and cingulate cortices of psychiatric patients. (a) Ct values from the qPCR
analysis of the expression of NOX1–NOX5 are shown. ND, not detected. Only values above a threshold of Ct= 35 (dotted line) were used for
further analysis. The expression of (b) NOX4 was unchanged, whereas NOX2 (c) was decreased in prefrontal cortex (PFC) of patients with
bipolar disorder. The expression of (d) NOX2 and (e) p47phox were decreased in cingulate cortex of bipolar patients. (f) Signiﬁcant correlation
was observed for NOX2 expression in PFC and in cingulate cortex, Spearman ρ and P-value are shown on the graph. Data is presented as
median. *ANOVA Kruskal–Wallis test followed by Dunn’s multiple comparison test. Cont, control group (black); BD, bipolar disorder (red); SZ,
schizophrenia (green).
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Laboratories) and detected with 3,3-diaminobenzidinetetrahydrochloride
hydrate (DAB, Sigma-Aldrich, St Louis, MO, USA) and H2O2. For PFC, the
images were acquired using a Digital Image Hub (Leica Biosystems, Wetzlar,
Germany) and number of brown/white objects was quantiﬁed using in-house
—developed software analyzed as previously described.19
Statistical analysis
Spearman’s rank correlations were calculated for the relationship between
NOX2 expression and all available clinical data to determine whether any
other factors were contributing to the variation seen in the expression. The
difference between two groups was studied with the Mann–Whitney U
test; groups of more than two were studied using the nonparametric
Kruskal–Wallis method with the application of a Dunn’s correction for
multiple comparisons. Data is presented as median on all ﬁgures. To
examine for effects of continuous confounding measures, we performed
Spearman’s correlations on measures that emerged as signiﬁcant with the
nonparametric analyses of variance. There were nine continuous
confounding measures available for this analysis (post-mortem interval,
age, estimated lifetime exposure to neuroleptics, age of illness onset,
illness duration, brain pH, brain weight, and freezer or ﬁxation storage
time). There were also three non-continuous confounding measures
(hemisphere, gender, and any current or past history of substance abuse)
available for analysis. These were used as grouping measures for Mann–
Whitney U tests for any abnormal measure. The level of signiﬁcance was
deﬁned as Po0.05. All statistical analyses were performed using Sigma
Stat (version 3.0, San Jose, CA, USA), GraphPad Prism (version 4.0, La Jolla,
CA, USA) and SPSS (version 10, Armonk, NY, USA).
Blindness of the study
Researchers performing qPCR of NOX isoforms and NOX2 immunostaining
analysis were blinded to patient diagnosis as well as to socio-demographic
distributions. Patients were initially identiﬁed by a code. Blindness of the
study was broken after returning results to the Stanley Medical Research
Institute. Further qPCR using the NOX2 subunit p47phox (NCF1) and the
microglia markers CD11b, Iba1 and CD68 were subsequently performed.
RESULTS
Expression of NOX mRNA in prefrontal and cingulate cortices of
psychiatric patients
To evaluate the expression of NOX NADPH oxidases in brain
regions associated with psychiatric disorders we obtained RNA
samples from PFC and cingulate cortex from the Stanley Array
Collection. The expression of mRNA for ﬁve NOX isoforms (NOX1–
NOX5) in PFC was measured by qPCR. We did not analyze the
expression of two other members of NOX family: DUOX1 and
DUOX2 as previous qPCR and RNAseq data suggest that they are
not expressed in the brain tissue.20,21 We found medium to high
levels of NOX2 and NOX4 mRNA, and very low levels of NOX1 and
NOX5, whereas NOX3 was below the detection level (Figure 1a).
We conﬁrmed the identity of NOX2 and NOX4 by sequencing the
qPCR products (data not shown).
The Stanley Array Collection is a collection of mRNA samples
from patients with BD, SZ and healthy individuals without
psychiatric diagnosis. We analyzed the expression of NOX2 and
NOX4 in disease groups. No changes of NOX4 mRNA levels were
found in the three analyzed groups (Figure 1b). In contrast to what
has been suggested from mouse studies,22,23 we did not observe
signiﬁcant changes of NOX2 expression in the SZ group. However,
we found a signiﬁcant decrease of NOX2 mRNA levels in bipolar
patients (n= 28; median = 0.4316; interquartile range (IQR)
= 0.4271), which distinguished this group both from controls
(n= 32; median = 0.7413; IQR= 0.5687) and from schizophrenic
patients (n= 31; median = 0.6802; IQR= 0.5181) (Figure 1c). Inter-
estingly, this decrease was not limited only to PFC. Levels of NOX2
and its subunit p47phox were also decreased in cingulate cortex
(Figures 1e and f). Overall, a strong correlation was found for
NOX2 mRNA expression between the two brain regions
(Figure 1d).
Association of NOX expression with demographic, social and
technical factors
The analysis of demographic factors (age, sex, brain weight and
hemisphere), technical factors related to sample preparation
(post-mortem interval, refrigerator period (from estimated time
of death to refrigeration of body) and of disease-related factors
(age of onset, time in the hospital) showed no statistically
signiﬁcant correlation neither with NOX2 expression in PFC and
cingulate cortex (Supplementary Figure 1) nor with NOX4
expression in PFC (Supplementary Figure 2). The expression of
NOX2 signiﬁcantly correlated with brain pH (Supplementary
Figures 1i and s). It was previously shown that the brain pH in
bipolar patients from the Stanley Array Collection was lower than
in the control group.24 This observation can have multiple
interpretations including post-mortem sample preservation or
changes of brain pH inherent to disease. In our data set, the brain
pH was also lower in bipolar patient as well as in SZ patients as
compared with the controls (data not shown). It has been
suggested that decreased pH is associated with lower RNA
quality.24 However, it is unlikely that the decrease in NOX2
expression in bipolar patients is due to the lower pH for the
following reasons: (i) the expression of NOX4 was not affected
(Supplementary Figures 2i and j); (ii) no association between NOX2
and post-mortem interval (Supplementary Figures 1e and m) nor
with refrigerator interval (Supplementary Figures 1f and n) were
found; (iii) NOX2 mRNA levels were not decreased in SZ patients
and (iv) NOX2 levels were signiﬁcantly lower even after elimina-
tion from the analysis of samples with pH lower than 6.4 in PFC
(Supplementary Figures 1j and t). Furthermore, no statistical
impact of VPA prescription or substance abuse on pH was
identiﬁed (data not shown).
Out of the social factors (smoking, alcohol consumption and
substance abuse) and of the disease-related factors (psychotic
features, suicide status and duration of illness) only substance
abuse was signiﬁcantly associated with decreased expression of
NOX2 both in PFC (Figure 2b: no/low users; n= 58; median = 0.739;
IQR = 0.5534 vs users; n= 32; median = 04372; IQR = 0.3971) and in
cingulate cortex (Figure 2h: no/low users; n= 58; median = 0.3429;
IQR= 0.2239 vs users; n= 32; median = 0.2485; IQR = 0.2024).
Localization of NOX2 in microglia and correlation with microglial
markers
To address the question of NOX2 localization in the brain of
psychiatric patients, we stained parafﬁn-embedded sections of
PFC with a monoclonal anti-human NOX2 antibody.
The Mo48 antibody is currently the only validated antibody
speciﬁc for human NOX2 in immunohistochemistry applications.
Its epitope is known25 and Mo48 is routinely used (also with the
7D5 monoclonal antibody) to characterize patients with NOX2 loss
of function.26 Immunohistochemical analysis detected NOX2
staining mainly in microglia (Figures 3a–f). We quantiﬁed microglia
separately from gray and white matter because of intrinsic
differences in microglial density in these regions.27 No difference
in object count was detected between different disease groups in
gray (Figure 3g) and in white matter (Figure 3h) in spite of a trend
for a decrease in the white matter of the PFC.
Recently RNASeq analysis of speciﬁc cell populations of the
mouse and human CNS (neurons, astrocytes, oligodendrocytes,
microglia/macrophages and endothelial cells) has been made
publicly available.20 We therefore analyzed the expression of
NOX2 (aka CYBB) in these samples (Figure 3i). By far, the largest
expression of NOX2 was found in microglia/macrophages. There
was also some degree of NOX2 expression in the oligodendrocyte
fraction; however, according to the authors of the publication,
there was an ~ 5% contamination of microglia/macrophages
population within the oligodendrocyte fraction. Finally, the
amount of NOX2 in astrocytes, endothelial cells and neurons
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was negligible. This corroborates our immunohistochemical data
suggesting that the large majority of NOX2 in the studied human
brain samples are localized to microglia/macrophages.
If NOX2 is indeed located in microglia, one would predict a
correlation between the expression of NOX2 and microglia
markers. We therefore performed additional qPCR with mRNA
samples from the cingulate cortex to evaluate the expression of
microglial markers. We found a signiﬁcant correlation between the
expression of NOX2 and microglial markers: CD11b, Spearman
ρ= 0.87, Po0.0001 (Figure 3j); CD68, Spearman ρ= 0.85,
Po0.0001 (Supplementary Figure 3a); Iba1, Spearman ρ= 0.34,
Po0.0008 (Supplementary Figure 3b). The analysis of microglial
markers in patient groups showed that the expression of CD11b
(Figure 3k) and CD68 (Figure 3l) was signiﬁcantly decreased in BD
group as compared with control. There were no signiﬁcant
differences for IBA-1 (Figure 3m). This is in line with the weaker
correlation between NOX2 and Iba1 mRNA expression (ρ= 0.34;
see above and Supplementary Figure 3b). This difference might
be due to different activation stages of microglia in these
samples and thereby may illustrate the relative speciﬁcity of
microglial markers in identifying surveillant versus activated
microglia.
Association of NOX expression with prescribed medications and
substance abuse
Almost all patients in our study were prescribed multiple
medications including antipsychotics, mood stabilizers and anti-
depressants. Most patients, have a history of smoking, alcohol
consumption and substance abuse, in particular, those with BDs.
These substances might impact microglia homeostasis.28 By
investigating the association of NOX expression levels with the
documented prescribed medications, we found that the decrease
of NOX2 levels in PFC and in cingulate cortex of BD patients was
signiﬁcantly associated with the prescription of VPA (Figures 4a
and c). Such association was not found for NOX4 (PFC, Figure 4b).
There was also a decrease in microglia markers associated with
VPA prescription (CD11b (Figure 4d), CD68 (Figure 4e), but not
with Iba1 (Figure 4g). The prescription of another frequently used
mood stabilizer, lithium, was not associated with the decrease in
NOX2 levels nor with microglial markers. Note that no information
is available regarding the fact that patients would actually use
VPA. No association between VPA prescription and a particular BD
subtype was observed (data not shown).
As VPA is often prescribed to both BD and SZ patients, we
compared these two patient groups. NOX2 expression was lower
in BD patients receiving VPA than in schizophrenic patients to
Figure 2. Association of NOX2 expression with social and disease-relevant factors. NOX2 mRNA expression in prefrontal cortex (PFC) and in
cingulate cortex was not signiﬁcantly associated with alcohol consumption (a, g) and smoking (c, i). NOX2 expression was signiﬁcantly lower
in the patients with substance abuse (b, h). No association with the disease-relevant factors such as psychotic features (d, j), suicide status (e,
k) and duration of illness (f, l) were found. **Po0.01, Mann–Whitney U test.
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Figure 3. NOX2 localization in microglia and correlation with microglial markers. (a) Representative images of NOX2 staining in the indicated
patient groups are shown for gray matter (a–c) and for white matter (d–f). Inset depicts typical microglial morphology in these samples. No
signiﬁcant differences in the number of objects were detected in gray matter (g) nor in white matter (h). (i) RNAseq data showing NOX2
expression in central nervous system (CNS) cell populations in healthy human brain.20 (j) Signiﬁcant correlation with CD11b expression was
found for NOX2 in cingulate cortex. Spearman ρ and P-values are shown on the graph. The expression of microglial markers CD11b (k), CD68
(l) but not Iba1 (m) is decreased in the cingulate cortex of BD patients. *ANOVA Kruskal–Wallis test followed by Dunn’s multiple
comparison test.
NOX2 expression in human psychiatric brains
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whom the drug has been prescribed (Figures 5a and c). There was
no statistically signiﬁcant difference between schizophrenic
patients receiving or not receiving VPA (albeit there was a trend).
These data were corroborated by expression levels of the
activated microglia marker CD11b (Figure 5d). In contrast, VPA
has no impact on NOX4 levels in our analysis (Figure 5b). We also
performed a similar analysis among subpopulations of patients
with documented substance abuse. NOX2 expression was
signiﬁcantly decreased only between BD patients with substance
use and abstinent SZ in PFC and cingulate cortex, although there
was a trend for a decrease of NOX2 and CD11b in BD users. No
difference was detected for NOX4. The groups were probably too
small to generate more signiﬁcant data. In addition, the substance
use is a vague terminology and most likely represents very diverse
drug-related behaviors and various types of recreational drug with
fundamentally different mode of action.
DISCUSSION
In this study we demonstrate—as opposed to what had been
predicted based on animal experimentation—that there is no
increase of NOX2 expression in schizophrenic patients. Unexpect-
edly, however, we found that NOX2 expression was decreased in
patients with BD. This decrease was essentially seen in patients
that were either prescribed VPA or in patients with a history of
substance abuse. NOX2 expression was mostly found in microglia
suggesting a decreased activity of brain inﬂammatory cells in a
subset of patients with BD.
We evaluated the expression of the ROS-generating NADPH
oxidases NOX1-5 in human brain samples from the Stanley
Collection (schizophrenic, BDs and control). The overall pattern of
expression was as follows: we found high mRNA expression levels
of the NOX2 and NOX4, whereas NOX1 and NOX5 were at the limit
of detection and NOX3 below detection levels. Although the
expression of NOX2 in the human brain has been convincingly
documented before, the question of which cell type within the
CNS expresses NOX2 is still a matter of debate. Expression in
microglia has been previously shown,19,21 but NOX2 expression
has been suggested in mature neurons,29 as well as adult neural
stem cells.30 The interpretation of these—at least in part contra-
dictory—results is complex: (i) in many instances, antibodies with
a poorly documented speciﬁcity have been used (discussed in ref.
14); (ii) the cell type that expresses NOX2 might depend on the
brain region and developmental state; and (iii) disease-speciﬁc
expression of NOX2 might also exist. Our ﬁndings in prefrontal
and cingulate cortices of psychiatric patients and control
individuals argue in favor of a speciﬁc expression of NOX2 in
microglia: (i) brain immunostaining with the speciﬁc and fully
validated NOX2 antibody mo48[ref. 18] detected cells with an
obvious microglial morphology, and (ii) NOX2 expression corre-
lated with macrophage/microglial markers CD11b, CD68 and Iba1.
Along these lines, data extracted from an RNAseq study31
indicates strong microglial enrichment of NOX2 and its subunits
p47phox, p67phox and p40phox, whereas NOX2 was virtually absent
in neurons. Data from mouse experiments suggest that NOX2 is
also expressed in adult neural stem cells of the subventricular
zone and the dentate gyrus.30,32 However, this has not been
investigated in humans, and, in addition, neural stem cells are
most likely absent in the regions (cingulate and prefrontal
cortices) investigated in our study. We did not address the cellular
Figure 4. Association between mood stabilizers and NOX2 expression in patients with BD. Valproic acid (VPA) but not lithium prescription is
associated with decreased levels of NOX2 (a) but not NOX4 (b) in prefrontal cortex (PFC); and with decreased levels of NOX2 (c) and microglial
markers CD11b (d), CD86 (e) and Iba1 (f) in cingulate cortex. The axis legend applies for the graphs of both rows. *, **ANOVA Kruskal–Wallis
test followed by Dunn’s multiple comparison test.
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CNS localization of NOX4 by immunohistochemistry, but recent
RNAseq data indicate a strong NOX4 enrichment in human brain
endothelial cells,33 whereas microarray data indicate NOX4
expression in human pericytes.34
A major goal of our study was to understand whether NOX2
expression was altered in psychiatric disease. SZ and BD are
distinct and yet overlapping clinical entities. The etiologies of the
two psychiatric diseases remain poorly understood. Several lines
of evidence argue for a role of inﬂammation35 and oxidative
dysregulation.36 Oxidative modiﬁcations in the brain of schizo-
phrenic patients have been widely reported10 making NOX2 an
attractive candidate to be involved in the disease process. On the
basis of animal models of psychosis,37 a role of increased NOX2
activity and expression in the pathophysiology of schizophrenia
has been suggested. Other NOX isoforms have hardly been
studied in this context. To our knowledge, our study represents
the ﬁrst systematic analysis of NOX enzymes in samples from
patients with psychiatric disease. The NOX1, NOX3 and NOX5
isoforms showed very low expression levels, and for this reason
we did not perform in-depth analysis. NOX4 expression levels
were high, but we did not observe any changes between patient
groups, socio-demographic factors, and technical parameters.
However, marked variations in NOX2 expression levels were
detected. Our initial working hypothesis, that there might be an
increased level of NOX2 in schizophrenic patients was not
conﬁrmed. Indeed, NOX2 levels were virtually identical in
schizophrenic patients and in control. Unexpectedly, however,
we found that BD patients—as compared to controls and
schizophrenic patients—had signiﬁcantly lower levels of NOX2
in both brain regions tested. The most widely used microglia
marker Iba1, is not changed in BD patients. However, the
activation-dependent microglia markers CD11b and CD68 follow
a similar pattern as NOX2, suggesting that microglia activation
rather than microglia number is affected. This robust decrease of
NOX2 and other microglial activation markers in BD post-mortem
material is a novel and unexpected ﬁnding. Indeed, most
publications support a role of exaggerated microglia activity and
increased pro-inﬂammatory cytokines in psychiatric diseases. Our
study challenges this theory. Importantly, our results indicate that
there are differences in microglial response in BD and SZ.
Our results raise the possibility that decreased NOX2 expression
is linked to BD. At this point, however, it is difﬁcult to distinguish
whether this is an intrinsic feature of the disease or whether this is
due to external factors. At the ﬁrst glance, our data appears to
favor the latter explanation: decreased NOX2 expression is limited
to a subgroup of BD patients, namely patients that have been
prescribed VPA, and patients with a history of heavy substance
abuse. Thus, one working hypothesis might be that VPA and
recreational drugs suppress NOX2 expression. VPA is drug with a
complex mode of actions, including inhibitions of histone
deacetylases.38 It is used since the 1960s for the treatment of
several CNS disorders, including epilepsy and BDs. High concen-
trations of VPA have been shown to be inhibitory to human
microglia39 or even toxic to mouse microglia40 and/or rat
peripheral leukocytes.41 Thus, the decreased NOX2 expression
and microglial activation could be due to VPA treatment. Although
this possibility is real, we are not aware of a common biochemical
pathway that links the use of VPA and recreational drugs. No
information on the compliance towards VPA and the type of
substances abused by the patients is available for the Stanley
Collection. Also, a decrease in NOX2 is observed only in BD, but
not in SZ patients with VPA prescription. For this reason, an
alternative explanation should also be considered. It is concei-
vable that patients that are prescribed VPA and patients prone to
Figure 5. Comparison of valproic acid (VPA) prescription and substance abuse in bipolar disorder (BD) and schizophrenia (SZ) patients. NOX2
expression is lower in BD patients prescribed with VPA compared with other BD patients and SZ patients with or without VPA prescription in
both prefrontal cortex (PFC) (a) and cingulate cortex (c). NOX4 is not changed (b) and CD11b shows the same pattern as NOX2 in cingulate
cortex (d). Similar analysis for substance abuse shows no difference in NOX2 and NOX4 expression in PFC (e, f) and only a difference in NOX2
expression in the cingulate cortex for BP patients with substance abuse compared with abstinent SZ patients (g). No differences in CD11b
expression was detected between subgroups. The axis legend applies for the graphs of both rows. *, **ANOVA Kruskal–Wallis test followed by
Dunn’s multiple comparison test.
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substance abuse belong to a pathophysiologically distinct
subgroup of BD patients. Indeed, VPA is often prescribed to BD
patients that are not responsive or intolerant to lithium.42 Thus, a
more generalized microglia pathology might contribute to the
pathophysiology of this subgroup of BD patients. Primary
alterations in microglia function have been implicated in
autism43 and obsessive compulsive behavior.44 Assuming that
decreased microglia activation in BD is not a drug-induced
epiphenomenon, how could it contribute to disease progression?
Microglia has a key role in brain homeostasis by regulating
neurogenesis both during development and in adults by
removing superﬂuous synapses (synaptic pruning).45,46 Thus, the
decreased microglia activity in BD patients might alter synaptic
pruning. Alternatively, one might consider a paracrine pathway
where NOX2-derived ROS regulate redox-sensitive transcription
factors and signaling in neural cells.
Altogether, our results demonstrate low microglial NOX2 in a
subgroup of patients with BD, whereas NOX2 expression and
microglial activation were unchanged in schizophrenia. The
decrease in NOX2 expression might either be secondary to VPA
and recreational drugs, or represent a pathophysiologically
relevant feature of a subgroup of BD patients. In the future, it
will be important to develop techniques of in vivo redox imaging
in the human brain, which will allow distinguishing between these
possibilities.
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